L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

NCT02631109 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Hemophagocytic Lymphohistiocytosis

Interventions

DRUG: Pegaspargase
DRUG: doxorubicin
DRUG: etoposide
DRUG: methylprednisolone

Sponsor

Beijing Friendship Hospital